Large-cap Health Care company Abbott Laboratories has moved 0.6% so far today on a volume of 1,901,120, compared to its average of 5,925,307. In contrast, the S&P 500 index moved 0.0%.
Abbott Laboratories trades -9.83% away from its average analyst target price of $116.1 per share. The 20 analysts following the stock have set target prices ranging from $100.0 to $133.0, and on average have given Abbott Laboratories a rating of buy.
If you are considering an investment in ABT, you'll want to know the following:
-
Abbott Laboratories's current price is 174.5% above its Graham number of $38.14, which implies that at its current valuation it does not offer a margin of safety
-
Abbott Laboratories has moved -2.0% over the last year, and the S&P 500 logged a change of 18.0%
-
Based on its trailing earnings per share of 2.94, Abbott Laboratories has a trailing 12 month Price to Earnings (P/E) ratio of 35.6 while the S&P 500 average is 15.97
-
ABT has a forward P/E ratio of 22.6 based on its forward 12 month price to earnings (EPS) of $4.63 per share
-
The company has a price to earnings growth (PEG) ratio of -11.71 — a number near or below 1 signifying that Abbott Laboratories is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 4.85 compared to its sector average of 4.08
-
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
-
Based in North Chicago, the company has 115,000 full time employees and a market cap of $181.75 Billion. Abbott Laboratories currently returns an annual dividend yield of 2.0%.